- Home
- BIIB vs DGX Comparison
BIIB vs DGX Comparison
Compare BIIB & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- DGX
- Stock Information
- Founded
- BIIB 1978
- DGX 1967
- Country
- BIIB United States
- DGX United States
- Employees
- BIIB N/A
- DGX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- DGX Medical Specialities
- Sector
- BIIB Health Care
- DGX Health Care
- Exchange
- BIIB Nasdaq
- DGX Nasdaq
- Market Cap
- BIIB 18.8B
- DGX 19.8B
- IPO Year
- BIIB 1991
- DGX 1996
- Fundamental
- Price
- BIIB $127.50
- DGX $166.38
- Analyst Decision
- BIIB Buy
- DGX Buy
- Analyst Count
- BIIB 27
- DGX 14
- Target Price
- BIIB $188.17
- DGX $185.07
- AVG Volume (30 Days)
- BIIB 1.2M
- DGX 897.3K
- Earning Date
- BIIB 07-31-2025
- DGX 07-22-2025
- Dividend Yield
- BIIB N/A
- DGX 1.90%
- EPS Growth
- BIIB 26.39
- DGX 6.41
- EPS
- BIIB 10.12
- DGX 7.91
- Revenue
- BIIB $9,816,400,000.00
- DGX $10,158,000,000.00
- Revenue This Year
- BIIB N/A
- DGX $10.38
- Revenue Next Year
- BIIB N/A
- DGX $4.03
- P/E Ratio
- BIIB $12.69
- DGX $21.29
- Revenue Growth
- BIIB 1.59
- DGX 9.38
- 52 Week Low
- BIIB $110.04
- DGX $137.71
- 52 Week High
- BIIB $236.48
- DGX $182.38
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- DGX 29.54
- Support Level
- BIIB $132.37
- DGX $171.29
- Resistance Level
- BIIB $137.84
- DGX $174.47
- Average True Range (ATR)
- BIIB 4.12
- DGX 3.04
- MACD
- BIIB 0.01
- DGX -1.39
- Stochastic Oscillator
- BIIB 25.82
- DGX 10.45
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.